{"DataElement":{"publicId":"6682261","version":"1","preferredName":"Prior Systemic Therapy Administered Type","preferredDefinition":"Information related to the type of prior systemic therapy administered.","longName":"2195087v1.0:6682251v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"2195087","version":"1","preferredName":"Prior Systemic Therapy Administered","preferredDefinition":"information related to the prior systemic therapy administered.","longName":"PRIOR_SYSTX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206845","version":"1","preferredName":"Prior Systemic Therapy","preferredDefinition":"Earlier in time or order.:(sis-TEM-ik THER-a-pee) Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","longName":"C25629:C15698","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-0AE3-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECF2382B-D848-4E2D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-01-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6682251","version":"1","preferredName":"Proir Systemic Therapy Administered Type","preferredDefinition":"The type of prior systemic therapy administered.","longName":"6682251v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"HD IL-2","valueDescription":"High dose Interleukin-2","ValueMeaning":{"publicId":"6682254","version":"1","preferredName":"High dose Interleukin-2","longName":"6682254v1.00","preferredDefinition":"A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells._Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Dose Chemotherapy","conceptCode":"C15807","definition":"A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"853C4BED-D097-17E5-E053-F662850A007E","latestVersionIndicator":"Yes","beginDate":"2019-03-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"853C4BED-D0B0-17E5-E053-F662850A007E","beginDate":"2019-03-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-03-29","modifiedBy":"ONEDATA","dateModified":"2019-03-29","deletedIndicator":"No"},{"value":"Prior adjuvant sunitinib","valueDescription":"Prior Adjuvant Sunitinib","ValueMeaning":{"publicId":"6682255","version":"1","preferredName":"Prior Adjuvant Sunitinib","longName":"6682255","preferredDefinition":"Earlier in time or order.: An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.: An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Adjuvant","conceptCode":"C2140","definition":"An agent that enhances the activity or therapeutic effect of another pharmacologic substance without having much, if any, therapeutic impact by itself.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Sunitinib","conceptCode":"C71622","definition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"853C4BED-D0BE-17E5-E053-F662850A007E","latestVersionIndicator":"Yes","beginDate":"2019-03-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-03-29","modifiedBy":"ONEDATA","dateModified":"2019-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"853C4BED-D0D7-17E5-E053-F662850A007E","beginDate":"2019-03-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-03-29","modifiedBy":"ONEDATA","dateModified":"2019-03-29","deletedIndicator":"No"},{"value":"No prior systemic therapy","valueDescription":"Negation Prior Systemic Therapy","ValueMeaning":{"publicId":"6682256","version":"1","preferredName":"Negation Prior Systemic Therapy","longName":"6682256","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Earlier in time or order.: Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"853C4BED-D0E5-17E5-E053-F662850A007E","latestVersionIndicator":"Yes","beginDate":"2019-03-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-03-29","modifiedBy":"ONEDATA","dateModified":"2019-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"853C4BED-D0FE-17E5-E053-F662850A007E","beginDate":"2019-03-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-03-29","modifiedBy":"ONEDATA","dateModified":"2019-03-29","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AECF371B-E202-78BF-E053-4EBD850AE4D2","beginDate":"2020-09-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-08","modifiedBy":"ONEDATA","dateModified":"2020-09-08","deletedIndicator":"No"},{"value":"Docetaxel with ADT","valueDescription":"Docetaxel With Antiandrogen Therapy","ValueMeaning":{"publicId":"7413011","version":"1","preferredName":"Docetaxel With Antiandrogen Therapy","longName":"7413011","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04): Used to indicate the presence of something or someone.: Treatment with drugs used to block production or interfere with the action of male sex hormones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antiandrogen Therapy","conceptCode":"C15481","definition":"A therapeutic regimen that utilizes pharmaceuticals to reduce serum levels of male sex hormones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AECF371B-E210-78BF-E053-4EBD850AE4D2","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-08","modifiedBy":"ONEDATA","dateModified":"2020-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AECF371B-E229-78BF-E053-4EBD850AE4D2","beginDate":"2020-09-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-08","modifiedBy":"ONEDATA","dateModified":"2020-09-08","deletedIndicator":"No"},{"value":"Novel antiandrogen with ADT","valueDescription":"New Anti-Androgen With Antiandrogen Therapy","ValueMeaning":{"publicId":"7413013","version":"1","preferredName":"New Anti-Androgen With Antiandrogen Therapy","longName":"7413013","preferredDefinition":"Having no previous example or precedent or parallel; of a kind not seen before.: Substances that inhibit or antagonize the biosynthesis or biologic effects of androgens by either antagonizing the responsiveness of androgen sensitive tissues or competing with their binding sites.: Used to indicate the presence of something or someone.: Treatment with drugs used to block production or interfere with the action of male sex hormones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"New","conceptCode":"C25586","definition":"Having no previous example or precedent or parallel; of a kind not seen before.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Anti-Androgen","conceptCode":"C242","definition":"Substances that inhibit or antagonize the biosynthesis or biologic effects of androgens by either antagonizing the responsiveness of androgen sensitive tissues or competing with their binding sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antiandrogen Therapy","conceptCode":"C15481","definition":"A therapeutic regimen that utilizes pharmaceuticals to reduce serum levels of male sex hormones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AECF371B-E239-78BF-E053-4EBD850AE4D2","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-08","modifiedBy":"ONEDATA","dateModified":"2020-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AECF371B-E252-78BF-E053-4EBD850AE4D2","beginDate":"2020-09-08","endDate":null,"createdBy":"MORENOC","dateCreated":"2020-09-08","modifiedBy":"ONEDATA","dateModified":"2020-09-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"853C4BED-D064-17E5-E053-F662850A007E","latestVersionIndicator":"Yes","beginDate":"2019-03-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":"11/6/2019: CM Released as part of draft content review","administrativeNotes":"2023.8.14 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Prior systemic therapy for th","type":"Preferred Question Text","description":"Prior systemic therapy for this tumor","url":null,"context":"Alliance"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Prior Systemic Therapies","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"853C5DA0-FD3A-6A23-E053-F662850A22CA","latestVersionIndicator":"Yes","beginDate":"2019-03-29","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-03-29","modifiedBy":"MORENOC","dateModified":"2020-09-08","changeDescription":"11/6/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}